Cisplatin-docetaxel induction chemotherapy for patients with nasopharyngeal carcinoma in a non-endemic cohort.

Nasopharyngeal carcinoma cisplatin concomitant chemoradiotherapy docetaxel induction chemotherapy

Journal

Journal of chemotherapy (Florence, Italy)
ISSN: 1973-9478
Titre abrégé: J Chemother
Pays: England
ID NLM: 8907348

Informations de publication

Date de publication:
21 May 2023
Historique:
medline: 22 5 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: aheadofprint

Résumé

This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic NPC. IC comprised docetaxel (75 mg/m

Identifiants

pubmed: 37211862
doi: 10.1080/1120009X.2023.2215090
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Kübra Özkaya Toraman (K)

Department of Radiation Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

Rasim Meral (R)

Department of Radiation Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

Ahmet Nafiz Karadeniz (AN)

Department of Radiation Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Gizem Kaval (G)

Department of Radiation Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Mert Başaran (M)

Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

Meltem Ekenel (M)

Department of Medical Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.

Musa Altun (M)

Department of Radiation Oncology, Oncology Institute, Istanbul University, Istanbul, Turkey.
Department of Radiation Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Classifications MeSH